Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography

Krause, W.; Karras, Jürgen; Jakobs, U.

doi:10.1016/s0378-4347(00)84836-7

Cited by 14 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several HPLC methods have been reported for estimation of CAN in various biomatrices such as serum, plasma and urine [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26], however there are no published methods which have employed whole blood in liquid form or in the form of DBS. Many of the methods have several limitations such as lack of selectivity [10,11], low sensitivity [13,17] or large volume of biomatrix required (1 ml plasma) [18,25] and as such are not suitable for estimation of CAN in very low volume paediatric blood samples.…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a dried blood spot—LC–APCI–MS assay for estimation of canrenone in paediatric samples

Suyagh

Kole

Millership

et al. 2010

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Development and validation of a dried blood spot—LC–APCI–MS assay for estimation of canrenone in paediatric samples

Suyagh

Kole

Millership

et al. 2010

Journal of Chromatography B

View full text Add to dashboard Cite

“…It undergoes extensive metabolism, while the dethioacetylated metabolite canrenone was earlier considered to be the major active metabolite of spironolactone [ 210 ]. Later on it was suggested that 7 alphathiomethylspirolactone is the main metabolite.…”

Section: Spironolactonementioning

confidence: 99%

Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

Balakumar

Jagadeesh

2015

Pathophysiology and Pharmacotherapy of Cardiovascular Disease

View full text Add to dashboard Cite

Drugs with diversifi ed structure and class target the RAAS cascade at various levels. Beginning with the inhibition of renin from the juxtaglomerular cells of the kidney, it extends to the blockade of formation and actions of its principal component, Ang II, and its effector, aldosterone and its synthesis. Although all of them are very effi cacious in combating overactivation of RAAS, ACE inhibitors and ARBs stand out in the armamentarium of RAAS inhibitors. All of them are effective in lowering blood pressure but differ from each other in potency, pharmacokinetic properties and additional pharmacologic actions that are contributed by their unique functional groups. Therapeutic uses of RAAS blockers stem from the dynamics of the complex intertwined downstream signaling molecules that interact to contribute beyond blood pressure control. Thus, some of the ACE inhibitors and ARBs are also indicated in the treatment of heart failure, left ventricular dysfunction following myocardial infarction, and nephropathy in T2DM, reducing the risk of cardiovascular mortality, nonfatal myocardial infarction, and the risk of developing heart failure. Several studies have investigated the dual inhibition of the RAAS in hypertension and heart failure with an outcome of more adverse events without an increase in benefi t. While considering Ang II and aldosterone escape processes during ACE inhibitors and ARBs therapies, RAAS at the base level can be halted using aldosterone receptor antagonists for the management of hypertension and heart failure. InThe opinions expressed herein are those of GJ and do not necessarily refl ect those of the US Food and Drug Administration.

show abstract

“…These methods include quantification by spectrophotometry, 4,5 HPLC, [6][7][8][9][10][11][12] and capillary electrophoresis. 13 Although, there are no published analytical methods available for determination of SPI alone; but a thorough literature review revealed quite a few methods available for the determination of SPI in combination with its metabolites, [14][15][16][17][18][19] degradation products 20 and other drugs. [21][22][23][24][25][26][27] However, an intensive literature search revealed to the best of our knowledge that only eight methods are available for simultaneous determination of TOR and SPI.…”

Section: Introductionmentioning

confidence: 99%

Optimization and Validation of a Sensitive HPLC–PDA Method for Simultaneous Determination of Torasemide and Spironolactone in Human Plasma using Central Composite Design

Subramanian¹

2015

ACSi

View full text Add to dashboard Cite

A sensitive, accurate, precise and rapid HPLC-PDA method was developed and validated for the simultaneous determination of torasemide and spironolactone in human plasma using Design of experiments. Central composite design was used to optimize the method using content of acetonitrile, concentration of buffer and pH of mobile phase as independent variables, while the retention factor of spironolactone, resolution between torasemide and phenobarbitone; and retention time of phenobarbitone were chosen as dependent variables. The chromatographic separation was achieved on Phenomenex C 18 column and the mobile phase comprising 20 mM potassium dihydrogen ortho phosphate buffer (pH-3.2) and acetonitrile in 82.5:17.5 v/v pumped at a flow rate of 1.0 mL min-1. The method was validated according to USFDA guidelines in terms of selectivity, linearity, accuracy, precision, recovery and stability. The limit of quantitation values were 80 and 50 ng mL-1 for torasemide and spironolactone respectively. Furthermore, the sensitivity and simplicity of the method suggests the validity of method for routine clinical studies.

show abstract

Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography

Cited by 14 publications

References 11 publications

Development and validation of a dried blood spot—LC–APCI–MS assay for estimation of canrenone in paediatric samples

Development and validation of a dried blood spot—LC–APCI–MS assay for estimation of canrenone in paediatric samples

Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases

Optimization and Validation of a Sensitive HPLC–PDA Method for Simultaneous Determination of Torasemide and Spironolactone in Human Plasma using Central Composite Design

Contact Info

Product

Resources

About